As a recombinant humanized monoclonal antibody, which can target and bind with VEGF, reduce neovascularization and inhibit tumor growth, bevacizumab was the first angiogenesis inhibitor approved for clinical use. The gene discussed is VEGFA; the disease is neoplasm.